about
New directions in antiplatelet therapyA Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.Cangrelor: a review on its mechanism of action and clinical development.Update on the clinical development of cangrelor.Mechanism of action and clinical development of platelet thrombin receptor antagonists.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Diabetes and antiplatelet therapy in acute coronary syndrome.Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.Platelet function and genetic testing.Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents.Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study.Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study.Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.Long-term follow-up after percutaneous treatment of the unprotected left main stenosis in high risk patients not suitable for bypass surgery.Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.Body mass index and acute coronary syndromes: paradox or confusion?CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Impact on delay times and characteristics of patients undergoing primary percutaneous coronary intervention in the southern metropolitan area of Barcelona after implementation of the infarction code program.Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound.Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration.Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients.IVUS Findings in Late and Very Late Stent Thrombosis. A Comparison Between Bare-metal and Drug-eluting Stents.Clopidogrel response variability: current status and future directions.Global risk score for choosing the best revascularization strategy in patients with unprotected left main stenosis.Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.IVUS-guided treatment strategies for definite late and very late stent thrombosis.Platelet function testing and risk of bleeding complications.Noninvasive Follow-Up of Patients With Spontaneous Coronary Artery Dissection With CT Angiography.Longitudinal deformation of drug-eluting stents: evaluation by multislice computed tomography.Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.Coronary perforation after bioresorbable vascular scaffold implantation.
P50
Q26824577-00FB79C3-EAE1-4273-AC53-4F7A29EDEDDAQ35893235-05439C2C-6042-4B91-A044-F31612E1F0EDQ37451509-FE3F51CA-81E4-4012-A325-5DFAE609B6F4Q37611039-3B0BAE5C-1D6E-4798-A9EB-69A9F0ADB8A2Q37776511-5B309471-2DBB-4AEE-ADB5-BF50D481CE92Q37776518-F48521E8-61DF-4704-9E7D-C691BC09E840Q37797795-7385940A-F07F-4FE8-8BFD-F4B8A72D886DQ37846051-326E23E2-CA32-4225-BE07-24302F94CA28Q37980265-084759FF-63AA-4A39-86F7-96F48A9FD634Q38153573-B0922C8C-EC35-4336-827F-7397745D0439Q38386870-8B3D1B0E-CACB-41CD-9DF1-0D5DB031982CQ38491857-1C84BCD3-A152-4C21-91A4-F22C720726F1Q38493656-DE702555-2788-41D3-81ED-CB211C0084DBQ38974706-3D85C20A-3372-45DA-B713-459D14CB976CQ39313895-5A3F4C7A-8316-4A8F-91F9-7018DD3C246BQ42880581-F779DF42-00E4-4922-A5A2-2EE66B1DDD24Q43133050-04EFB8A7-4AE5-4DFF-B4C7-BF8342037EE1Q43565637-20D7766D-499A-4AC7-91A1-E42FACD401D2Q43744458-E42B732A-085D-4F2E-BF60-1A29FD24158DQ44157858-A1D5182B-EB40-439C-B0D4-5389AF76F2B0Q44202078-F830FB6C-C08B-491F-992D-E4A15971E7DEQ44751386-66BCFCBB-DFEE-48D1-BC57-3841A38568E8Q45096352-4592AE29-F1F3-4BA0-B0A1-BD8BD8B82389Q45226003-6A4AE138-5823-452A-94BE-23F4205DCC8FQ45737175-57FC3242-B311-4362-B128-A5C85B4F75B2Q45907527-FB320135-D59B-4CEC-89BA-95E83CD9070AQ45995576-A16AEAFD-F0A5-4C3A-A744-92587A734DF1Q46290459-429D31DD-91CE-4538-B200-F1EB2257D154Q46678626-A11BDDB4-760D-4679-AAAB-02FF34A40CA5Q47654408-BB6ED9F6-58FF-40E5-892E-7D2BB5D95207Q50223666-C5E83F67-2384-4097-B7B7-291463B21E04Q50329075-DAAD1679-A221-4FD2-BE30-007EF94E9B63Q51136945-78515756-E8D5-42A5-B81D-4B8F55F9F312Q51306353-0C392BB4-354E-44E0-81C7-540AC8AFD407Q51598201-5F3E9DFB-4240-409C-816C-BA50C840DE90Q51836665-8BB1CF59-5195-4C70-822C-B1C3F2002841Q52990212-D65F684B-1410-403D-B1EE-0CDD67E23C6BQ53070833-B18E9892-1C91-40F1-AAB7-60A934B098D3Q53178855-572FDBFD-A313-4A8B-90EE-50921A26E5DBQ53252649-F262AE48-6B1C-48DE-9AED-FAEDBC49D9E9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
José L Ferreiro
@ast
José L Ferreiro
@en
José L Ferreiro
@es
José L Ferreiro
@nl
José L Ferreiro
@sl
type
label
José L Ferreiro
@ast
José L Ferreiro
@en
José L Ferreiro
@es
José L Ferreiro
@nl
José L Ferreiro
@sl
altLabel
Jose-Luis Ferreiro-Gutierrez
@en
José Luis Ferreiro-Gutiérrez
@en
prefLabel
José L Ferreiro
@ast
José L Ferreiro
@en
José L Ferreiro
@es
José L Ferreiro
@nl
José L Ferreiro
@sl
P1053
N-4431-2017
P106
P21
P31
P3829
P496
0000-0003-1202-9575